| Budget Amount *help |
¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2016: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2015: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2014: ¥2,600,000 (Direct Cost: ¥2,000,000、Indirect Cost: ¥600,000)
|
|---|
| Outline of Final Research Achievements |
Encephalomyeloradiculoneuroapthy (EMRN) is a devastating disorder involved in central and peripheral nervous systems. In 2014, we found autoantibodies against neutral glycolipids in EMRN were present and their titers well correlated to the status of clinical conditions. In this study, we explored biological activities of these autoantibodies and the molecular mechanisms how these autoantibodies are produced. The data disclosed the following facts; 1) all EMRN cases exhibit antibodies against neutral glycolipids, mainly to lactosylceramide in their sera and/or CSF; 2) clinical pictures of EMRN seemed rather uniform, but the reactivities against immune modulatory therapies showed varieties; 3) anti-neutral glycolipids antibodies are sensitive to fatty acid chain length of respective neutral glycolipids; 4) CSF samples from EMRN cases exhibited significant abnormal compositions of glycolipids compared with normal controls based upon the LC/MS/MS highly sensitive assay method.
|
